YaoGeJu

Company directoryChina company filings

Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference 44ce21256c

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

29 acceptance records as first applicant, grouped into 19 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

更年舒片 · No verified English name 1 records · Latest accepted 2026/04/09

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2601330Supplement2026/04/09Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
通关藤口服液(消癌平口服液) · No verified English name 2 records · Latest accepted 2026/02/15

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2600632Supplement2026/02/15Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
CYZB2400298Supplement2024/02/23Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
Lusutrombopag Tablets 1 records · Latest accepted 2025/11/05

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503872Generic2025/11/05Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
感冒炎咳灵糖浆 · No verified English name 3 records · Latest accepted 2025/11/01

Supplement · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2502469Supplement2025/11/01Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
CYZB2402219Supplement2024/11/12Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
CYZB2101303Supplement2021/07/09Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized; Wei Hai Ren Sheng Pharma Co., Ltd. romanizedCDE ↗
咽炎片 · No verified English name 2 records · Latest accepted 2025/10/18

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2502349Supplement2025/10/18Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized; Li Cai Gansu Xi Feng Pharmaceutical Co., Ltd. romanizedCDE ↗
CYZB2502348Supplement2025/10/18Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized; Li Cai Gansu Xi Feng Pharmaceutical Co., Ltd. romanizedCDE ↗
盆炎净口服液 · No verified English name 1 records · Latest accepted 2025/09/04

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2501919Supplement2025/09/04Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
苏黄止咳胶囊 · No verified English name 1 records · Latest accepted 2025/08/14

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZS2500009Generic2025/08/14Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
Finerenone Tablets 1 records · Latest accepted 2025/04/03

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2501256Generic2025/04/03Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
泌尿宁胶囊 · No verified English name 1 records · Latest accepted 2024/12/31

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2402664Supplement2024/12/31Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
痔炎消胶囊 · No verified English name 1 records · Latest accepted 2024/12/31

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2402663Supplement2024/12/31Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
藤黄健骨胶囊 · No verified English name 1 records · Latest accepted 2024/12/31

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2402665Supplement2024/12/31Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
复方聚乙二醇电解质散(II) · No verified English name 4 records · Latest accepted 2024/11/16

Supplement · 2Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2401911Supplement2024/11/16Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
CYHB2401910Supplement2024/11/16Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
CYHS2400285Generic2024/01/20Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
CYHS2400284Generic2024/01/20Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
Upadacitinib Sustained-release Tablets 1 records · Latest accepted 2024/10/16

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2403496Generic2024/10/16Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
九归强肾酒 · No verified English name 1 records · Latest accepted 2024/09/13

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2401760Supplement2024/09/13Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
杏仁止咳合剂 · No verified English name 2 records · Latest accepted 2024/03/05

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2400404Supplement2024/03/05Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized; Li Cai Gansu Xi Feng Pharmaceutical Co., Ltd. romanizedCDE ↗
CYZB2301828Supplement2023/09/20Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized; Li Cai Gansu Xi Feng Pharmaceutical Co., Ltd. romanizedCDE ↗
藿香正气合剂 · No verified English name 2 records · Latest accepted 2024/02/23

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2400299Supplement2024/02/23Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized; Li Cai Gansu Xi Feng Pharmaceutical Co., Ltd. romanizedCDE ↗
CYZB2301829Supplement2023/09/20Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized; Li Cai Gansu Xi Feng Pharmaceutical Co., Ltd. romanizedCDE ↗
复方维生素C聚乙二醇(3350)钠钾散 · No verified English name 1 records · Latest accepted 2024/02/06

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2400530Generic2024/02/06Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
莲芝消炎片 · No verified English name 1 records · Latest accepted 2023/06/07

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYZB2301059Supplement2023/06/07Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
Oseltamivir Phosphate For Oral Suspension 2 records · Latest accepted 2022/06/10

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200858Generic2022/06/10Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
CYHS2200857Generic2022/06/10Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

3 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Lusutrombopag Tablets CYHS2503872Generic2025/11/05Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
Finerenone Tablets CYHS2501256Generic2025/04/03Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
Upadacitinib Sustained-release Tablets CYHS2403496Generic2024/10/16Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗

Catalogue holder records

3 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
复方聚乙二醇(3350)电解质散(II) · No verified English nameYang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedYang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized国药准字H202559572025/11/18Generic approved under the new chemical-drug registration classificationCDE ↗
复方聚乙二醇(3350)电解质维C散 · No verified English nameYang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedYang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized国药准字H202547722025/06/30Generic approved under the new chemical-drug registration classificationCDE ↗
Oseltamivir Phosphate For Oral SuspensionYang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedYang Ling Ke Sen Biopharmaceutical Co., Ltd. romanized国药准字H202346272023/12/13Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

5 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
奥洛他定莫米松鼻喷雾剂 · No verified English name CYHL2600097Generic2026/09/10Xian Li Cai Pharmaceuticals Research and Development Co., Ltd. romanized; Shaanxi Li Cai Pharma Co., Ltd. romanized; Li Cai Gansu Xi Feng Pharmaceutical Co., Ltd. romanized; Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
痔炎消胶囊 · No verified English name CYZB2401734Supplement2024/09/11Li Cai Gansu Xi Feng Pharmaceutical Co., Ltd. romanized; Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
复方聚乙二醇电解质散(II) · No verified English name CYHS2401308Generic2024/04/30Shaanxi Li Cai Pharma Co., Ltd. romanized; Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
复方聚乙二醇电解质散(II) · No verified English name CYHS2401307Generic2024/04/30Shaanxi Li Cai Pharma Co., Ltd. romanized; Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗
泌尿宁胶囊 · No verified English name CYZB2302264Supplement2023/11/14Li Cai Gansu Xi Feng Pharmaceutical Co., Ltd. romanized; Yang Ling Ke Sen Biopharmaceutical Co., Ltd. romanizedCDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.